“Acute Myeloid Leukemia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Myeloid Leukemia Market.
The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Acute Myeloid Leukemia Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Acute Myeloid Leukemia and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as -
-
Oral
-
Intravenous
-
Subcutaneous
Molecule Type
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as -
-
Small molecule
-
Cell Therapy
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Major Clinical, Commercial, and Regulatory Developments in the Acute Myeloid Leukaemia Therapeutics Market
-
On January 30, 2023, Aptose Biosciences Inc. announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
-
On January 25, 2023, STORM Therapeutics Ltd. (STORM) presented new data on its lead candidate, the METTL3 inhibitor STC-15. The new data in AML preclinical models were presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome hosted in Austin, Texas, on the 23-25 of January.
-
On January 5, 2023, Jubilant Therapeutics announced that the United States Food and Drug Administration (US FDA) had granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).
In January 2021, Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, and GlycoMimetics announced APL-106 (uproleselan) had been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
-
In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) had granted orphan-drug designation (ODD) to the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).
Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Myeloid Leukemia Therapeutic Segment @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
Acute Myeloid Leukemia Therapeutics Landscape
There are approx. 260+ key companies developing Acute Myeloid Leukaemia therapies. Currently, Gamida Cell has its Acute Myeloid Leukaemia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Acute Myeloid Leukaemia Therapeutics Market Include:
GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
Acute Myeloid Leukaemia Drugs Covered in the Report Include:
-
Omidubicel: Gamida Cell
-
Uproleselan: GlycoMimetics
-
ALT 803: ImmunityBio
-
BPX-501: Bellicum Pharmaceuticals
-
ASTX727 [Decitabine and cedazuridine]: Astex Pharmaceuticals, Inc.
-
Dociparstat sodium (DSTAT, CX-01): Chimerix
-
IO-202: Immune Onc
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Acute Myeloid Leukemia Current Treatment Patterns
4. Acute Myeloid Leukemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Acute Myeloid Leukemia Late Stage Products (Phase-III)
7. Acute Myeloid Leukemia Mid-Stage Products (Phase-II)
8. Acute Myeloid Leukemia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Myeloid Leukemia Discontinued Products
13. Acute Myeloid Leukemia Product Profiles
14. Key Companies in the Acute Myeloid Leukemia Market
15. Key Products in the Acute Myeloid Leukemia Therapeutics Segment
16. Dormant and Discontinued Products
17. Acute Myeloid Leukemia Unmet Needs
18. Acute Myeloid Leukemia Future Perspectives
19. Acute Myeloid Leukemia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
